• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Psychiatry >Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study
【24h】

Health care use, drug treatment and comorbidity in patients with schizophrenia or non-affective psychosis in Sweden: a cross-sectional study

机译：瑞典精神分裂症或非情感性精神病患者的医疗保健使用，药物治疗和合并症：一项横断面研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

This study investigated the prevalence of schizophrenia (ICD-10?F 20) and of other non-affective psychosis (NAP, ICD-10?F 21 - F 29) in Sweden. It further assessed health care use, comorbidity and medication for these patient groups. Most studies either have a study population of patients with strictly defined schizophrenia or a psychosis population of which strict schizophrenia cases form a smaller set. The present study permits comparison of the two mutually exclusive patient groups using data at the individual level in the diagnosis of non-affective psychosis, use of health care, medical treatment and comorbidity by diagnosis or medical treatment. In 2012, data were extracted from a regional registry containing patient-level data on consultations, hospitalisations, diagnoses and dispensed drugs for the total population in the region of Stockholm (2.1 million inhabitants). The size of the total psychosis population was 18,769, of which 7284 had a diagnosis of schizophrenia. Crude prevalence rates and risk rates with 95% confidence intervals were calculated. In 2012, the prevalence of schizophrenia and NAP was 3.5/1000 and 5.5/1000, respectively. Schizophrenia was most common among patients aged 50–59?years and NAP most common among patients aged 40–49?years. Schizophrenia patients used psychiatric health care more often than the NAP patients but less overall inpatient care (78.6 vs. 60.0%). The most prevalent comorbidities were substance abuse/dependence (7.9% in the schizophrenia group vs. 11.7% in the NAP group), hypertension (7.9 vs. 9.7%) and diabetes (6.9 vs. 4.8%). The parenteral form of long-acting injectable antipsychotics was more often dispensed to patients with schizophrenia (10 vs. 2%). This study, analysing all diagnoses recorded in a large health region, confirmed prevalence rates found in previous studies. Schizophrenia patients use more psychiatric and less overall inpatient health care than NAP patients. Differences between the two patient groups in comorbidity and drug treatment were found. The registered rates of a substance abuse/dependence diagnosis were the most common comorbidity observed among the patients investigated. The observed differences between the schizophrenia and the NAP patients in health care consumption, comorbidity and drug treatment are relevant and warrant further studies.
机译：这项研究调查了瑞典的精神分裂症（ICD-10？F 20）和其他非情感性精神病（NAP，ICD-10？F 21-F 29）的患病率。它进一步评估了这些患者组的医疗保健使用，合并症和药物治疗。大多数研究要么是有严格定义的精神分裂症患者的研究人群，要么是由严格的精神分裂症病例组成的精神病人群。本研究允许使用个体水平的数据在非情感性精神病的诊断，医疗保健的使用，药物治疗以及通过诊断或药物治疗的合并症中使用个人水平的数据进行比较。 2012年，数据从区域登记册中提取，其中包含有关斯德哥尔摩地区总人口（210万居民）的咨询，住院，诊断和分配药物的患者水平数据。精神病总人口为18,769，其中7284被诊断为精神分裂症。以95％的置信区间计算了原油的流行率和风险率。 2012年，精神分裂症和NAP的患病率分别为3.5 / 1000和5.5 / 1000。精神分裂症最常见于50-59岁的患者，而NAP最常见于40-49岁的患者。精神分裂症患者比NAP患者更常使用精神病保健，但总体住院治疗较少（78.6比60.0％）。最普遍的合并症是药物滥用/依赖性（精神分裂症组为7.9％，NAP组为11.7％），高血压（7.9对9.7％）和糖尿病（6.9对4.8％）。长效注射抗精神病药的肠胃外形式通常分配给精神分裂症患者（10比2％）。这项研究分析了在大健康地区记录的所有诊断，证实了先前研究中发现的患病率。与NAP患者相比，精神分裂症患者使用更多的精神病学药物和更少的整体住院医疗服务。发现两组患者在合并症和药物治疗方面存在差异。在所研究的患者中，最常见的合并症是药物滥用/依赖性诊断的登记率。精神分裂症和NAP患者在医疗保健消费，合并症和药物治疗方面观察到的差异是相关的，值得进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号